BC-LI-0186

BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM) . BC-LI-0186 competitively binds to the RagD interacting site of LRS (Kd=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated MTOR mutants and the growth of rapamycin-resistant cancer cells. BC-LI-0186 is a promising agent for lung cancer research[1][2].

Product Specifications

CAS Number

[695207-56-8]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Aminoacyl-tRNA Synthetase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bc-li-0186.html

Concentration

10mM

Purity

99.20

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=C(N2N(C)C(C)=C(C(C)C)C2=O)C=C1)(NCCOC3=CC=CC=C3)=O

Molecular Formula

C22H27N3O4S

Molecular Weight

429.53

Precautions

H315, H319

References & Citations

[1]Jong Hyun Kim, et al. Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction. Nat Commun. 2017 Sep 29;8 (1) :732.